Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

102
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
102
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

725
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
725
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

119
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
119

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Folate as a Key Regulator of Animal Intestinal Homeostasis: From Metabolism to Microbiota and Barrier Function.

Animals : an open access journal from MDPI·2026
Same author

Association between hepatic vein Doppler and echocardiographic diastolic indices with invasively measured right ventricular filling pressures in pediatric pulmonary arterial hypertension.

International journal of cardiology·2026
Same author

Van der Waals strain hardening and large uniform tensile elongation in GaSe.

Nature materials·2026
Same author

A Rediscussion of the Definitions of the Onset and End of Atrial Strains.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography·2026
Same author

Machine learning models for predicting microvascular invasion in hepatocellular carcinoma with three-dimensional whole-lesion <sup>18</sup>F-FDG PET radiomics.

Hellenic journal of nuclear medicine·2026
Same author

Photo-Tautomerization-Driven Energy Transfer at the Hole-Transport Interface Stabilizes Efficient Inverted Perovskite Solar Cells.

Angewandte Chemie (International ed. in English)·2026

Related Experiment Video

Updated: Jul 29, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K

Treatment of Hepatitis E.

Wei Hui1, Linlin Wei2

  • 1Chronic Disease Management Center, Youan Hospital, Capital Medical University, Beijing, China.

Advances in Experimental Medicine and Biology
|May 24, 2023
PubMed
Summary

Hepatitis E virus (HEV) infection can be acute or chronic. Ribavirin is recommended for chronic HEV and high-risk acute cases to prevent liver failure and reduce the need for liver transplantation.

Keywords:
Acute hepatitis EChronic hepatitis EHEV-related liver failurePegylated interferonRibavirinTreatment

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.3K

Related Experiment Videos

Last Updated: Jul 29, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.3K

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis E virus (HEV) is a leading cause of acute hepatitis globally.
  • HEV infections can progress to chronic disease, particularly in immunocompromised individuals.
  • Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are severe complications of HEV.

Purpose of the Study:

  • To review current therapeutic strategies for Hepatitis E virus (HEV) infection.
  • To highlight the role of ribavirin in managing chronic HEV and preventing severe outcomes in acute cases.
  • To discuss supportive care and management of complications in HEV infection.

Main Methods:

  • Literature review of HEV treatment guidelines and clinical studies.
  • Analysis of therapeutic options including ribavirin, pegylated interferon α, and supportive care.
  • Evaluation of management strategies for HEV-related liver failure and complications.

Main Results:

  • Ribavirin is recommended as first-line therapy for chronic HEV and beneficial in high-risk acute HEV to prevent ALF/ACLF.
  • Pegylated interferon α has shown efficacy but carries significant side effects.
  • Supportive care, including vitamins, albumin, and measures for cholestasis and jaundice, is crucial.
  • Liver support devices and liver transplantation (LT) are options for severe liver failure.

Conclusions:

  • Ribavirin offers significant benefits for chronic HEV and in preventing severe outcomes in acute HEV.
  • Management of HEV requires a multi-faceted approach, including supportive care and complication management.
  • Liver transplantation remains the definitive treatment for end-stage liver failure due to HEV.